natgillin/translations-raw huggingface dataset:
Statistically significant reductions in white blood cell (WBC) count were observed in the controlled studies at 24 hours post-injection, from a mean value of 8.9 to a mean value of 8.0 (× 103/mm3), but remained within the normal range, and returned to their pre-injection values by the time of the next measurement at 10 days. 
Statistično značilna zmanjšanja števila belih krvnih celic so bila pri kontroliranih študijah opažena 24 ur po injiciranju zdravila, in sicer od srednje vrednosti 8,9 x 103/mm3 na 8,0 x 103/mm3, a so ostala znotraj normalnega razpona in so se do naslednjega štetja po 10 dneh povrnila na vrednosti pred injiciranjem zdravila.
An evaluation of potential clinical impact of LeukoScan demonstrated that LeukoScan could change clinical management in 50.2% or improve clinical outcome in 43.4% of the 175 evaluable patients with suspected osteomyelitis. 
Ovrednotenje potencialnega kliničnega vpliva zdravila LeukoScan je pokazalo, da bi zdravilo LeukoScan lahko spremenilo klinično obravnavo pri 50.2% ali izboljšalo klinični izid pri 43,4% izmed 175 ocenljivih bolnikov s sumom na osteomielitis.
You will receive a single dose of 0.25 mg of LeukoScan. 
Dobili boste en odmerek 0,25 mg zdravila LeukoScan.
Data processing by filtered backprojection and reconstruction in three planes (transaxial, coronal, and sagittal) 
Priporočljiva je obdelava podatkov s filtrirano vzvratno projekcijo in rekonstrukcijo v treh ravninah (transaksialni,
This leaflet only applies to LeukoScan. 
To navodilo se nanaša samo na zdravilo LeukoScan.
One to eight hours later you will be placed on a special table and pictures will be taken with standard nuclear cameras to see where the infections are located. 
Eno do osem ur pozneje vas bodo položili na posebno mizo in naredili posnetke s standardnimi nuklearnimi kamerami, da bodo videli, na katerem mestu potekajo vnetja.
If so, no inferences concerning the underlying mechanism(s) responsible may be derived from the clinical laboratory results. 
Če je temu tako, iz kliničnih laboratorijskih izvidov ni mogoče izpeljati sklepov o osnovnih odgovornih mehanizmih (mehanizmu).
Single photon emission computed tomography (SPECT) imaging can also be conducted and may aid in differentiating osteomyelitis from soft tissue infections. 
Opravljena je lahko tudi enofotonska izsevna tomografija (SPECT), ki lahko služi kot pomoč pri razločevanju osteomielitisa od infekcij mehkih tkiv.
LeukoScan is prepared for a single injection. 
Zdravilo LeukoScan je pripravljeno za enkratno injiciranje.
• If you are breast feeding, you should stop breast feeding your baby for at least 24 hours after you 
• Če dojite, morate po prejetju zdravila LeukoScan prenehati dojiti svojega otroka za najmanj 24 ur.
Obtain 900 ± 200 MBq of freshly eluted 99mTc sodium pertechnetate eluate from any commercial source which has been eluted within the past 24 hours. 
Vzemite 900 ± 200 MBq sveže izpranega 99mTc eluata natrijevega pertehnetata iz kateregakoli komercialno dostopnega vira, ki je bil izpran v zadnjih 24 urah.
Alternative techniques which do not involve ionising radiation should be considered. 
Razmisliti je potrebno tudi o alternativnih tehnikah, ki ne
In vitro studies have demonstrated that LeukoScan has no effect on either up-regulation or downregulation of granulocytes, but LeukoScan does appear to bind more avidly to activated rather than resting 
In vitro študije so pokazale, da zdravilo LeukoScan nima učinka na povišanje ali znižanje števila granulocitov, toda zdi se, da se zdravilo LeukoScan raje veže na aktivirane kot na mirujoče granulocite.
It is unknown whether the changes in WBC or eosinophil counts observed, although of no clinical significance, are due to a transient effect on WBC function. 
Ni znano, če so opažene spremembe v številu belih krvnih celic in eozinofilcev, čeprav klinično nepomembne, posledica prehodnega vpliva na funkcijo belih krvnih celic.
The following minor, self-limiting, rare adverse events were reported in the clinical trials and considered at least possibly related to LeukoScan: eosinophilia (3); and facial rash (1). 
Pri kliničnih študijah so poročali o naslednjih manj pomembnih, samoomejujočih, redkih neželenih dogodkih, za katere so menili, da obstaja vsaj možnost, da so povezani z zdravilom LeukoScan: eozinofilija (3) in izpuščaj po obrazu (1).
On the basis of two controlled clinical trials of LeukoScan to demonstrate the safety and effectiveness of this product for defining the presence and location of osteomyelitis, in a total of 175 evaluable patients, LeukoScan had a sensitivity of 88.2%, a specificity of 65.6%, an accuracy of 76.6%, a positive predictive value of 70.8%, and a negative predictive value of 85.5%. 
Na osnovi dveh kontroliranih kliničnih študij zdravila LeukoScan, s katerima so želeli dokazati varnost in učinkovitost zdravila pri definiranju prisotnosti in lokacije osteomielitisa, skupno na 175 ocenljivih bolnikih, je imelo zdravilo LeukoScan 88,2% občutljivost, 65,6% specifičnost, 76,6% natančnost, pozitivno napovedno vrednost 70,8% in negativno napovedno vrednost 85,5%.
Where uncertainty exists, it is important that radiation exposure should be the minimum consistent with achieving the desired clinical information. 
V primeru dvoma je pomembno, da je izpostavitev sevanju le tolikšna, kot je najmanj potrebno za pridobitev željene klinične informacije.
This suggests that imaging can be accomplished anytime between one and eight hours after injection (at the convenience of the nuclear 
To dejstvo pove, da je preiskava lahko izvršena kadarkoli v časovnem obdobju ene do osmih ur po injiciranju (tako, da je najugodneje za oddelek
The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic result. 
Aplicirana aktivnost mora biti tolikšna, da je rezultirajoče sevanje z ozirom na potrebo po pridobitvi nameravanega diagnostičnega rezultata kolikor je mogoče nizko.
What LeukoScan looks like and contents of the pack 
IZGLED ZDRAVILA LEUKOSCAN IN VSEBINA PAKIRANJA
The antibody is able to bind to the surface of white blood cells which infiltrate the area of infection. 
Protitelo se je sposobno vezati na površino belih krvnih celic, ki se nabirajo na področju vnetja.
Since LeukoScan cross-reacts with CEA, it should be borne in mind that it may interact with CEA 
Ker zdravilo LeukoScan navzkrižno reagira s CEA (karcinoembrionski antigen), je potrebno upoštevati, da lahko reagira s tumorji, ki proizvajajo CEA.
LeukoScan is an antibody fragment which is linked to a radioactive substance called technetium. 
Zdravilo LeukoScan je fragment (delček) protitelesa, vezan na radioaktivno snov, ki se imenuje tehnecij.
The Type I glass vial is closed with a grey butyl rubber stopper with a green flip-off seal. 
Steklena viala (steklo tipa I) je zaprta s sivim z zamaškom iz butilne gume z zeleno zaporko z varnostnim
Administration of 750 MBq LeukoScan will give an estimated absorbed dose of 4.1 mGy to an embryo or fetus at an early stage. 
Vnos 750 MBq zdravila LeukoScan pomeni ocenjeno absorbirano dozo sevanja 4,1 mGy na zarodek ali plod v zgodnjem stadiju razvoja.
By contrast, in non-infected subjects, transient increases in WBC count were seen 24 hours after LeukoScan administration. 
Nasprotno so pri osebah, ki niso bile okužene, opazili prehoden porast števila belih krvnih celic v času 24 ur po vnosu zdravila LeukoScan.
No studies on the effects on the ability to drive and use machines have been performed. 
Vpliv na sposobnost upravljanja vozil in strojev Študije o vplivu na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
Clean the rubber closure of each vial such as with an alcohol wipe. 
Očistite gumijasti zamašek vsake viale z blazinico, namočeno v alkohol.
In subjects with HAMA, there may be a greater chance of hypersensitivity reactions and 
Pri osebah s HAMA lahko obstaja večja verjetnost za nastanek preobčutljivostnih reakcij in zmanjšano učinkovitost slikanja.
Planar imaging in all views necessary to adequately visualise the affected area at 1-8 h post-injection with at least 500 k counts or ten minutes per view should be made. 
Eno do osem ur po injiciranju naj bo pravljeno ploskovno snemanje iz vseh smeri, ki so potrebne za vizualizacijo prizadetega področja, in sicer z najmanj 500 000 impulzi oziroma v trajanju 10 minut za posamezno smer.
LeukoScan is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic 
Zdravilo LeukoScan je indicirano za diagnostično slikanje za določitev mesta in obsega okužbe ali vnetja kosti pri bolnikih, pri katerih obstaja sum na osteomielitis, vključno z bolniki, ki imajo razjede na
The doctor does this by using a special imaging camera that reveals areas of radioactivity to see where the infections are located. 
Zdravniku pri tem pomaga uporaba posebne kamere, ki zaznava področja radioaktivnosti, s čimer lahko vidi, na katerem mestu v telesu poteka vnetje.
However, due to the low dose of protein administered and the short half-life of 99mTc, dosage adjustment is probably not 
Vseeno zaradi nizkega odmerka vnešenih beljakovin in kratkega razpolovnega časa 99mTc prilagoditev odmerka pri teh
You must then not be given LeukoScan. 
V tem primeru zdravila LeukoScan ne smete prejeti.
QUALITATIVE AND QUANTITATIVE COMPOSITION Kit for the preparation of 99mTc-labelled LeukoScan. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Komplet za pripravo 99mTc označenega zdravila LeukoScan
INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS Quality control 
NAVODILA ZA PRIPRAVO RADIOFARMAKOV
Formal studies have not been performed in patients with renal or hepatic impairment. 
Uradne študije na bolnikih z okvarjenim delovanjem ledvic ali jeter niso bile izvedene.
The antibody (IMMU-MN3) recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker, carcinoembryonic antigen (CEA). 
Protitelo (IMMU-MN3) prepozna antigensko strukturo površinskega glikoproteina (NCA-90) granulocitov in tumorskega označevalca, karcinoembrionskega antigena (CEA).
The maximum amount of LeukoScan [99mTc] that can be administered safely has not been determined. 
4.9 Preveliko odmerjanje Največja količina zdravila LeukoScan [99mTc], ki je lahko varno aplicirana, ni bila določena.
LeukoScan [99mTc] can be stored at room temperature after formulation. 
Zdravilo LeukoScan [99mTc] se po pripravi lahko shranjuje pri sobni temperaturi.
LeukoScan is not recommended for use in children. 
Uporaba zdravila LeukoScan pri otrocih ni priporočljiva.
At one hour after infusion, the blood level was 34% of baseline, 17% at four hours and 7% of baseline at 24 hours. 
Eno uro po infuziji so krvne vrednosti znašale 34% izhodiščne vrednosti, štiri ure po infuziji 17% izhodiščne vrednosti in 24 ur po infuziji 7% izhodiščne vrednosti.
When the radioactive antibody binds to the white blood cells, your doctor can determine where the infection is located by using a special imaging camera that reveals areas of radioactivity. 
Ko se radioaktivno protitelo veže na bele krvne celice, lahko vaš zdravnik z uporabo posebne kamere, ki zaznava področja radioaktivnosti, določi, na katerem mestu v telesu poteka vnetje.
The maximum amount of LeukoScan that can be administered has not been determined. 
Največja količina zdravila LeukoScan, ki je lahko dana bolniku, ni bila določena.
The product is more sensitive (93.9% vs. 80.6%), but less specific (51.6% vs. 72.9%), in diagnosing osteomyelitis in patients with diabetic foot ulcers than in patients with other sites of long bone osteomyelitis. 
Zdravilo je pri diagnosticiranju osteomielitisa pri bolnikih z diabetičnimi razjedami stopal bolj občutljivo (93,9% vs 80,6%), toda manj specifično (51,6% vs 72,9%) kakor pri bolnikih z drugimi lokalizacijami osteomielitisa dolgih kosti.
Appropriate cardiopulmonary resuscitation facilities and trained personnel should be available for immediate use in the event of an adverse reaction. 
V primeru neželene reakcije mora biti za takojšnjo uporabo na razpolago vsa oprema za kardiopulmonalno reanimacijo in ustrezno usposobljeno osebje.
In clinical trials involving over 350 patients, no induction of human anti-mouse antibody (HAMA) to antibody fragments has been observed nor has there been any elevation of HAMA levels in patients with 
V kliničnih študijah, ki so vključevale preko 350 bolnikov, niso opazili indukcije nastanka človeških protiteles proti mišjemu antigenu (HAMA) zaradi vnosa fragmentov mišjih protiteles, ravno tako pa pri bolnikih, ki so HAMA že razvili, niso opazili porasta HAMA vrednosti.
Technetium [99mTc] disintegrates with the emission of gamma radiation with an energy of 140 keV and a half life of 6 hours to technetium [99Tc] which can be regarded as quasi stable. 
Tehnecij [99mTc] z emisijo gama žarčenja z energijo 140 KeV in razpolovnim časom, ki znaša 6 ur, razpada na tehnecij [99Tc], ki je kvazi stabilen.
This radiopharmaceutical may be received, used and administered only by authorised persons in designated clinical settings. 
Ta radiofarmak sme biti prevzet, uporabljen in apliciran samo s strani pooblaščenih oseb v določenih kliničnih ustanovah.
• Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
• Radiofarmake je potrebno pripraviti na način, ki bo zadoščal tako zaščiti pred sevanjem kakor tudi farmacevtskim zahtevam po kakovosti.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR 
A. IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
However, in vitro granulocyte function tests did not show significant changes when the sulesomab was added. 
Vendar pa in vitro funkcijski testi granulocitov po dodatku sulezomaba niso pokazali
• This radiopharmaceutical may be received, used and administered only by authorised persons in designated clinical settings. 
• Ta radiofarmak sme biti prevzet, uporabljen in apliciran samo s strani pooblaščenih oseb v določenih kliničnih ustanovah.
LeukoScan is a sterile, lyophilised formulation, containing 0.31 mg of sulesomab per vial and includes 0.22 mg stannous chloride dihydrate, 3.2 mg potassium sodium tartrate tetrahydrate, 7.4 mg sodium acetate trihydrate, 5.5 mg sodium chloride, glacial acetic acid (trace), hydrochloric acid (trace), 37.8 mg sucrose, nitrogen (vacuum). 
LeukoScan je sterilen, liofiliziran pripravek, ki v posamezni viali vsebuje 0,31 mg sulezomaba in vključuje 0,22 mg kositrovega klorida dihidrata, 3,2 mg kalijevega natrijevega tartrata tetrahidrata, 7,4 mg natrijevega acetata trihidrata, 5,5 mg natrijevega klorida, koncentrirano ocetno kislino (v sledovih), klorovodikovo kislino (v sledovih), 37,8 mg saharoze, dušik (vakuum).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
Any unused product or waste material should be disposed of in accordance with local requirements. 
Vsa neporabljena količina zdravila ali odpadni material morata biti odstranjena v skladu z lokalnimi predpisi.
* Effective Dose Equivalent and Effective Dose are in units of µSv/MBq. 
povprečna doza μGy/MBq ekvivalent efektivne doze efektivna doza * Ekvivalent efektivne doze in efektivna doza sta izražena v enotah µSv/MBq.
Method and/or route(s) of administration 
Postopek in/ali pot(i) uporabe zdravila
In clinical trials, single doses of 1.0 mg of LeukoScan radiolabelled with 900 ± 200 MBq of 99mTc were administered to 11 patients with various types of infection and there were no adverse reactions at this 
V kliničnih študijah so bile posamezne doze 1,0 mg zdravila LeukoScan, ki je bil radiološko označen z 900 ± 200 MBq 99mTc, aplicirane 11 bolnikom z različnimi tipi infekcij in pri teh odmerkih niso opazili neželenih
LeukoScan has not been employed to diagnose osteomyelitis in patients with sickle cell anaemia. 
Zdravilo LeukoScan ni bilo uporabljeno za diagnosticiranje osteomielitisa pri bolnikih s srpasto celično
SPECIAL STORAGE CONDITIONS Store in a refrigerator (2ºC-8ºC). 
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte v hladilniku (2 °C - 8 °C).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS (VIAL LABEL) 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH (VIALA)
Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
Radiofarmake je potrebno pripraviti na način, ki bo zadoščal tako zaščiti pred sevanjem kakor tudi farmacevtskim zahtevam po kakovosti.
Following reconstitution, 1 ml sodium pertechnetate [99mTc] is added. 
Po rekonstituciji dodamo 1 ml raztopine natrijevega pertehnetata [99mTc].
Radiopharmaceutical agents should be used only by qualified personnel with appropriate government authorisation for the use and manipulation of radionuclides. 
Radiofarmake sme uporabljati samo strokovno usposobljeno osebje z ustreznim uradnim pooblastilom za uporabo in ravnanje z radionuklidi.
In a subgroup of patients in whom LeukoScan was compared directly to the currently available 111Inlabelled (occasionally 99mTc-labelled) autologous white blood cell (WBC) scanning test, LeukoScan showed a statistically significant increase in sensitivity over that achieved by WBC scanning (87.7% vs. 72.6%, p = 0.003 by McNemar's Test), with no discernible decrease in specificity as compared to WBC 
V podskupini bolnikov, pri katerih je bilo zdravilo LeukoScan neposredno primerjano s trenutno razpoložljivim z 111In označenim (priložnostno z 99mTc označenim) avtolognim presejalnim testom z belimi krvnimi celicami, je zdravilo LeukoScan v primerjavi s presejalnim testom z belimi krvnimi celicami pokazalo statistično pomemben porast občutljivosti (87,7% vs 72,6%, p = 0,003, ob uporabi McNemarovega testa), brez razločnega zmanjšanja specifičnosti v primerjavi s slikanjem z označenimi belimi krvnimi celicami (67,1% vs 69,4%).
The radiolabelled solution should be administered as an intravenous injection. 
Z radioaktivnim izotopom označena raztopina mora biti aplicirana v obliki intravenske injekcije.
Following reconstitution, unused radiopharmaceutical and vial should be handled as radioactive waste and disposed of in accordance with local requirements. 
Po rekonstituciji morata biti vsa neporabljena količina radiofarmaka in viala tretirana kot radioaktivni odpadek in morata biti odstranjena v skladu z lokalnimi
• Radiopharmaceutical agents should be used only by qualified personnel with appropriate government authorisation for the use and manipulation of radionuclides. 
• Radiofarmake sme uporabljati samo strokovno usposobljeno osebje z ustreznim uradnim pooblastilom za uporabo in ravnanje z radionuklidi.
Patients who have previously received murine monoclonal antibody products are more likely to have HAMA. 
Pri bolnikih, ki so predhodno že prejemali zdravila, ki vsebujejo glodalska monoklonalna protitelesa, je verjetnost, da bodo razvili HAMA, večja.
• You should not be given LeukoScan if you are pregnant. 
• Če ste noseči, ne smete prejeti zdravila LeukoScan.
The imaging agent, technetium-99m LeukoScan [technetium-99m sulesomab] is formed by reconstitution of the contents of the LeukoScan vial with 0.5 mL sodium chloride for injection followed by the addition of 1100 MBq of sodium pertechnetate [99mTc] in 1 mL of Sodium Chloride for Injection. 
Sredstvo za prikazovanje, tehnecij-99m LeukoScan (tehnecij-99m sulezomab), nastane pri rekonstituciji vsebine viale zdravila LeukoScan z 0,5 ml raztopine natrijevega klorida za injiciranje, ki ji sledi dodatek 1100 MBq natrijevega pertehnetata [99mTc] v 1 ml raztopine natrijevega klorida za injiciranje.
• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, 
• Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
Each vial contains stannous chloride, sodium chloride, sodium potassium tartrate, sodium acetate, sucrose, 
Vsaka viala vsebuje kositrov klorid, natrijev klorid, natrijev kalijev tartrat, natrijev acetat, saharozo, dušik.
Swirl and shake the vial contents gently for 30 seconds to insure dissolution. 
30 sekund nežno vrtite in stresajte vialo, da se bo vsebina raztopila.
When a bone scan is negative, imaging with LeukoScan may rarely show a positive response and this may indicate early osteomyelitis. 
Če je rentgenski posnetek kosti pozitiven in slikanje z LeukoScanom daje negativen rezultat, infekcija ni Če je rentgenski posnetek kosti negativen, slikanje z LeukoScanom v redkih primerih lahko daje pozitivni odgovor, kar lahko pomeni zgodnjo stopnjo osteomielitisa.
LeukoScan is not expected to bind to leukocytes in patients with paroxysmal nocturnal hemoglobinuria. 
Ni pričakovano, da bi se zdravilo LeukoScan vezalo na levkocite bolnikov s paroksizmalno nočno
Due to the short six-hour, half-life of 99mTc, a dose of less than 1 mSv in mother's milk can be expected 24 hours after the administration of LeukoScan [99mTc]. 
Zaradi kratke razpolovne dobe 99m-Tc, ki znaša 6 ur, se odmerek, ki je manjši od 1 mSv, v materinem mleku lahko pričakuje 24 ur po vnosu zdravila
If the administration is considered necessary, breast feeding should be interrupted and the expressed feeds discarded. 
Če je vnos radiofarmaka nujen, je potrebno dojenje prekiniti in mleko zavreči.
One vial prepared so as to contain 0.31 mg lyophilised LeukoScan monoclonal antibody fragment. 
Ena viala je pripravljena tako, da vsebuje 0,31 mg liofiliziranih LeucoScan fragmentov monoklonalnih
Hydrochloric Acid (Trace) Sodium Potassium Tartrate, Tetrahydrate Sodium Acetate, Trihydrate 
natrijev klorid klorovodikova kislina (sledovi) natrijev acetat trihidrat
After mixing with Tc, the final product must be disposed of as radioactive waste in accordance with local law. 
Po mešanju s tehnecijem mora biti končni produkt odstranjen kakor radioaktivni odpadek v skladu z
Pharmacotherapeutic group: Diagnostic Radiopharmaceuticals. 
Farmakoterapevtska skupina: Radiofarmaki za diagnostiko oznaka ATC: VO4D
Each 3 ml vial contains 0.31 mg sulesomab (IMMU-MN3 murine Fab′-SH antigranulocyte monoclonal antibody fragments) for the preparation of 99mTc labelled LeukoScan. 
Ena 3 ml viala vsebuje 0,31 mg sulezomaba (IMMU-MN3 fragmenti Fab'-SH antigranulocitnih monoklonalnih protiteles glodalcev) za pripravo 99mTc označenega zdravila LeukoScan.
Readministration should only be considered in patients whose sera are negative for human anti-mouse antibody (HAMA) elevation in the fragment assay. 
O ponovnem vnosu je mogoče razmisliti le pri bolnikih, katerih preiskava serumskih fragmentov je dala negativen rezultat na človeška protitelesa proti mišjim antigenom (HAMA).
• After use, the container should be disposed of as radioactive waste. 
• Po uporabi je potrebno vsebnik zavreči kot radioaktivni odpadek.
The estimated absorbed radiation doses to an average adult patient (70 kg) from an intravenous administration of LeukoScan labeled with 750 MBq of technetium-99m are provided in Table 1. 
Ocenjene absorbirane doze sevanja za povprečnega odraslega bolnika (70 kg) po intravenskem vnosu zdravila LeukoScan, označenega s 750 MBq tehnecija-99m so navedene v tabeli 1.
There was essentially no difference in the detection of the presence or absence of osteomyelitis between the 1-2 hour timepoint and the 5-8 hour timepoint after injection. 
Če je bila preiskava opravljena 1-2 uri ali pa 5-8 ur po injiciranju, se rezultati zaznavanja prisotnosti oziroma odsotnosti osteomielitisa niso bistveno razlikovali.
PACKAGE LEAFLET: INFORMATION FOR THE USER LeukoScan (0.31 powder for solution for injection) (sulesomab) 
NAVODILO ZA UPORABO INFORMACIJA ZA UPORABNIKA LeukoScan (0,31 prašek za raztopino za injiciranje) sulezomaba